XHKG
2297
Market cap24mUSD
May 19, Last price
0.16HKD
1D
0.00%
1Q
12.33%
IPO
-96.57%
Name
Rainmed Medical Ltd
Chart & Performance
P/E
—
P/S
4.44
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
40m
-45.61%
Net income
-113m
L-2.02%
CFO
0k
P
Profile
Rainmed Medical Limited, a medical device company, focus on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microvascular resistance systems. The company offers FlashAngio caFFR System, a coronary angiography-derived fractional flow reserve measurement system, which calculates FFR values based on a three-dimensional model of the coronary arterial system restored from two angiograms and FlashAngio caIMR System, a non-invasive microcirculatory lesion diagnosis and treatment system. It is also involved in developing intelligent angiographic injection, flash robot vascular intervention navigation operation system, and flash renal denervation systems. The company was founded in 2014 and is headquartered in Suzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 39,824 -45.61% | 73,219 -12.42% | 83,604 2.96% | ||
Cost of revenue | 149,241 | 156,771 | 166,045 | ||
Unusual Expense (Income) | |||||
NOPBT | (109,417) | (83,552) | (82,441) | ||
NOPBT Margin | |||||
Operating Taxes | 242 | (22) | (5,450) | ||
Tax Rate | |||||
NOPAT | (109,659) | (83,530) | (76,991) | ||
Net income | (113,496) -2.02% | (115,830) -91.39% | (1,345,963) 112.42% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 126,990 | ||||
BB yield | -9.12% | ||||
| Debt | |||||
Debt current | 21,001 | 7,956 | 25,403 | ||
Long-term debt | 7,579 | 16,475 | 14,553 | ||
Deferred revenue | |||||
Other long-term liabilities | 232 | ||||
Net debt | (176,968) | (310,851) | (539,003) | ||
| Cash flow | |||||
Cash from operating activities | (124,289) | (111,219) | |||
CAPEX | (84,681) | (29,821) | |||
Cash from investing activities | 180,294 | (515,744) | |||
Cash from financing activities | (15,882) | 120,733 | |||
FCF | (142,028) | (53,208) | (186,939) | ||
| Balance | |||||
Cash | 205,548 | 335,282 | 578,959 | ||
Long term investments | |||||
Excess cash | 203,557 | 331,621 | 574,779 | ||
Stockholders' equity | 409,912 | 456,505 | 618,636 | ||
Invested Capital | 232,166 | 208,392 | 66,564 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 1,134,960 | 1,167,799 | 898,232 | ||
Price | 0.17 -60.23% | 0.43 -72.26% | 1.55 | ||
Market cap | 194,078 -61.35% | 502,154 -63.93% | 1,392,260 | ||
EV | 20,027 | 196,266 | 853,257 | ||
EBITDA | (109,417) | (61,315) | (65,779) | ||
EV/EBITDA | |||||
Interest | 1,309 | 760 | |||
Interest/NOPBT | |||||